Squalamine

Squalamine

SCHEMBL29673379

CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O.C[C@H](O)C(=O)O.C[C@H](O)C(=O)O

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC9A3

The experimentally established mechanism targets of Squalamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.90
SLC10A1 Q14973 4/20 0.50
NR1H4 Q96RI1 7/20 0.49
GPBAR1 Q8TDU6 8/20 0.48
SLC10A2 Q12908 4/20 0.47
ABCB11 O95342 3/20 0.47
ENPP2 Q13822 2/20 0.47
ABCC4 O15439 1/20 0.47
PLA2G1B P04054 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
LMNA P02545 1/20 0.46
CYP2C19 P33261 1/20 0.46
CHRM2 P08172 1/20 0.46
ADRA2A P08913 1/20 0.46
ADRA1A P35348 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CISD1 Q9NZ45 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Squalamine SCHEMBL313361 1.00 PTPN1 (0.90) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL29673380 0.99 PTPN1 (0.89) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL22397773 0.97 PTPN1 (0.86) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL14430016 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL22356672 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL21248627 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL20850040 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL12836 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL17359656 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2
Squalamine SCHEMBL18838926 0.96 PTPN1 (0.97) PTPN1SLC10A1NR1H4GPBAR1SLC10A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11440936-B2 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same ENTERIN, INC. (US) 2022-09-13 US disclosed
US-11419879-B2 Methods for treating and preventing viral infections ENTERIN, INC. (US) 2022-08-23 US disclosed
US-20220220148-A1 METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME ENTERIN INC. (US) 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220148-A1 METHODS AND COMPOSITIONS FOR STIMULATION OF THE INTESTINAL ENTEROENDOCRINE SYSTEM FOR TREATING DISEASES OR CONDITIONS RELATED TO THE SAME SI, VIP, ASNS PTPN1 4093/4885SLC10A1 577/4885NR1H4 296/4885
US-11440936-B2 Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same SI, VIP, ASNS PTPN1 4093/4885SLC10A1 577/4885NR1H4 296/4885
US-11419879-B2 Methods for treating and preventing viral infections STING1, TSLP, MAVS PTPN1 2620/4885SLC10A1 114/4885NR1H4 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.